Nav: Home

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable

February 06, 2020

Following the first U.S. test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies - for months. The results from this Phase 1 clinical trial suggest the gene editing approach was safe and feasible, which until now has been uncertain, and the findings represent an important step toward the ultimate goal of using gene editing to help a patient's immune system attack cancer. CRISPR-Cas9 gene editing provides a powerful tool to improve the natural ability of human T cells to fight cancer. Though engineered T cell therapies are greatly advancing cancer treatment, whether CRISPR-Cas9 edited T cells would be tolerated and survive once reinfused into a human has been unknown. Here, focusing on three patients in their 60s with advanced cancers that didn't respond to standard treatments, Edward A. Stadtmauer and colleagues sought to test this. They removed T lymphocytes from these patients' blood and used CRISPR to delete genes from the cells that might interfere with the immune systems's ability to fight cancer. Next, the researchers used a virus to arm the T-cells to attack a protein typically found on cancer cells, NY-ESO-1. They infused the cells back into the patients and monitored cell engraftment and persistence. There were no toxicity-related side effects, the authors report, and the engineered T cells could be detected up to 9-months post-infusion. The work builds on earlier research developing adoptive T cell therapies led by Dr. Carl June, who was also part of this study. In a related Perspective, Jennifer Hamilton and Jennifer Doudna write, "these findings provide the cell engineering field with a guide for the safe production and non-immunogenic administration of gene edited somatic cells." They add: "The big question that remains unanswered by this study is whether gene-edited, engineered T cells are effective against advanced cancer," while also noting that the study by Stadtmauer and colleagues was restricted to editing protocols available in 2016, in which gene-edited T cells are likely less effective than they would be using newer technology available today.

American Association for the Advancement of Science

Related Advanced Cancer Articles:

Being overweight may raise your risk for advanced prostate cancer
A new study links being overweight in middle age and later adulthood to a greater risk of advanced prostate cancer.
New advances in the treatment of advanced lung cancer
The University of Barcelona (UB) and Hospital Clínic de Barcelona collaborate with Boehringer Ingelheim Inc. to improve the efficiency of nintedanib, an antiangiogenic and antifibrotic drug, for the treatment of lung cancer.
Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.
Advanced cancer drug shrinks and intercalates DNA
A new study published in EPJ E has found that the drug first forces itself between the strands of the DNA molecule's double helix, prising them apart.
Exercise associated with benefit to patients with advanced colorectal cancer
Patients with metastatic colorectal cancer who engaged in moderate exercise while undergoing chemotherapy tended to have delayed progression of their disease and fewer severe side effects from treatment, according to the results of a new study.
A new method to select the right treatment for advanced prostate cancer
Researchers at Karolinska Institutet in Sweden have identified blood-based biomarkers that may determine which patients will benefit from continued hormonal therapy for advanced prostate cancer.
New treatment approach for advanced anal cancer
A new approach to treating advanced anal cancer is safer and more effective than the most widely used current treatment, according to the first ever randomized clinical trial in this group of patients.
New 'Scoring' System for Advanced Colorectal Cancer
Georgios Margonis, M.D., Ph.D., a surgical oncology fellow at the Johns Hopkins University School of Medicine, and Matthew Weiss, M.D., surgical director of the Johns Hopkins Liver and Pancreas Cancer Multidisciplinary Clinics, report advances in efforts to improve the treatment and prognosis of colorectal cancers that have spread to the liver.
For mothers with advanced cancer, parenting concerns affect emotional well-being
A new study from the UNC Lineberger Comprehensive Cancer Center shows that parenting concerns have a significant impact on the mental and emotional health of women with advanced cancer.
How advanced nanotechnology can improve cancer care
A new Tel Aviv University study addresses the challenges of nanoparticle-based cancer-targeting strategies and suggests ways of refocusing the collaborative work of cancer researchers and clinicians.
More Advanced Cancer News and Advanced Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Climate Mindset
In the past few months, human beings have come together to fight a global threat. This hour, TED speakers explore how our response can be the catalyst to fight another global crisis: climate change. Guests include political strategist Tom Rivett-Carnac, diplomat Christiana Figueres, climate justice activist Xiye Bastida, and writer, illustrator, and artist Oliver Jeffers.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Speedy Beet
There are few musical moments more well-worn than the first four notes of Beethoven's Fifth Symphony. But in this short, we find out that Beethoven might have made a last-ditch effort to keep his music from ever feeling familiar, to keep pushing his listeners to a kind of psychological limit. Big thanks to our Brooklyn Philharmonic musicians: Deborah Buck and Suzy Perelman on violin, Arash Amini on cello, and Ah Ling Neu on viola. And check out The First Four Notes, Matthew Guerrieri's book on Beethoven's Fifth. Support Radiolab today at